NASDAQ:EDIT - Editas Medicine Stock Price, Forecast & News

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine Inc (NASDAQ:EDIT) issued its earnings results on Tuesday, November, 12th. The company reported ($0.66) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.07. The firm had revenue of $3.90 million for the quarter, compared to analysts' expectations of $4.72 million. Editas Medicine had a negative return on equity of 56.53% and a negative net margin of 842.47%. The firm's revenue for the quarter was down 73.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.32) earnings per share. View Editas Medicine's Earnings History.

Editas Medicine is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Editas Medicine.

Editas Medicine will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 brokers have issued 12-month price objectives for Editas Medicine's stock. Their forecasts range from $28.00 to $55.00. On average, they anticipate Editas Medicine's stock price to reach $37.33 in the next year. This suggests a possible upside of 57.6% from the stock's current price. View Analyst Price Targets for Editas Medicine.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Editas Medicine.

Media headlines about EDIT stock have been trending neutral on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Editas Medicine earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Editas Medicine.

Some companies that are related to Editas Medicine include Acceleron Pharma (XLRN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Allogene Therapeutics (ALLO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE) and Alector (ALEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Shopify (SHOP), Canopy Growth (CGC), TransEnterix (TRXC) and Intel (INTC).

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (9.65%), Nikko Asset Management Americas Inc. (9.65%), ARK Investment Management LLC (8.67%), State Street Corp (3.88%), Chevy Chase Trust Holdings Inc. (1.89%) and Credit Suisse AG (1.89%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Katrine Bosley and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.

EDIT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, State Street Corp, UBS Group AG, Rafferty Asset Management LLC, Crestwood Advisors Group LLC, Victory Capital Management Inc., Victory Capital Management Inc. and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, Cynthia Collins and Vickesh Myer. View Insider Buying and Selling for Editas Medicine.

EDIT stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Global Thematic Partners LLC, FMR LLC, Geode Capital Management LLC, Hussman Strategic Advisors Inc., Los Angeles Capital Management & Equity Research Inc., Goldman Sachs Group Inc. and Chevy Chase Trust Holdings Inc.. View Insider Buying and Selling for Editas Medicine.

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EDIT stock can currently be purchased for approximately $23.69.

Editas Medicine has a market capitalization of $1.22 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.View Additional Information About Editas Medicine.

The official website for Editas Medicine is http://www.editasmedicine.com/.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]